Market closedNon-fractional
Castle Biosciences/CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Castle Biosciences
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Ticker
CSTL
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Providers and Services
Headquarters
Friendswood, United States
Employees
638
Website
castlebiosciences.com
CSTL Metrics
BasicAdvanced
$587M
Market cap
-
P/E ratio
-$1.14
EPS
0.94
Beta
-
Dividend rate
Price and volume
Market cap
$587M
Beta
0.94
Financial strength
Current ratio
9.255
Quick ratio
8.821
Long term debt to equity
5.933
Total debt to equity
6.229
Interest coverage (TTM)
-1,996.48%
Management effectiveness
Return on assets (TTM)
-5.92%
Return on equity (TTM)
-7.82%
Valuation
Price to revenue (TTM)
2.29
Price to book
1.44
Price to tangible book (TTM)
2.01
Price to free cash flow (TTM)
-88.928
Growth
Revenue change (TTM)
64.71%
Earnings per share change (TTM)
-58.16%
3-year revenue growth
54.46%
3-year earnings per share growth
16.16%
What the Analysts think about CSTL
Analyst Ratings
Majority rating from 9 analysts.
CSTL Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$73M
10.29%
Net income
-$2.5M
-0.00%
Profit margin
-3.42%
-9.52%
CSTL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.26
-$0.10
-$0.09
-
Expected
-$0.92
-$0.76
-$0.54
-$0.33
-$0.29
Surprise
-23.50%
-65.96%
-81.35%
-72.87%
-
CSTL News
AllArticlesVideos
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® Test
Business Wire·2 weeks ago
Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
Business Wire·3 weeks ago
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $587M as of July 05, 2024.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 0 as of July 05, 2024.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Castle Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.